Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Non-Current Liabilities (2016 - 2018)

Fennec Pharmaceuticals (FENC) has disclosed Other Non-Current Liabilities for 7 consecutive years, with $167000.0 as the latest value for Q4 2017.

  • For the quarter ending Q4 2017, Other Non-Current Liabilities rose 406.06% year-over-year to $167000.0, compared with a TTM value of $167000.0 through Dec 2017, up 406.06%, and an annual FY2017 reading of $167000.0, up 406.06% over the prior year.
  • Other Non-Current Liabilities was $167000.0 for Q4 2017 at Fennec Pharmaceuticals, up from -$157000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $5.5 million in Q1 2014 and bottomed at -$157000.0 in Q2 2017.
  • Average Other Non-Current Liabilities over 5 years is $1.3 million, with a median of $167000.0 recorded in 2017.
  • The sharpest move saw Other Non-Current Liabilities surged 2342.59% in 2014, then plummeted 94.38% in 2016.
  • Year by year, Other Non-Current Liabilities stood at $54000.0 in 2013, then soared by 2342.59% to $1.3 million in 2014, then crashed by 93.78% to $82000.0 in 2015, then crashed by 59.76% to $33000.0 in 2016, then skyrocketed by 406.06% to $167000.0 in 2017.
  • Business Quant data shows Other Non-Current Liabilities for FENC at $167000.0 in Q4 2017, -$157000.0 in Q2 2017, and $71000.0 in Q1 2017.